Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. MiMedx Group, Inc.
  6. News
  7. Summary
    MDXG   US6024961012

MIMEDX GROUP, INC.

(MDXG)
  Report
Delayed Nasdaq  -  05/27 04:00:01 pm EDT
3.830 USD   +6.39%
05/26Leading Independent Proxy Advisory Firm ISS Recommends That MIMEDX Shareholders Vote 'FOR ALL' Of the Company's Proposals
AQ
05/25Leading Independent Proxy Advisory Firm ISS Recommends that MIMEDX Shareholders Vote “FOR ALL” of the Company's Proposals
AQ
05/24MIMEDX GROUP, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MiMedx Group, Inc. Provides Revenue Guidance for the Financial Year 2022

01/10/2022 | 08:00am EDT
share with twitter
share with LinkedIn
share with facebook

MiMedx Group, Inc. provides revenue guidance for the financial year 2022. For the period, the company expects annual revenue growth of 11% to 14% in the Company’s continuing portfolio of products.


© S&P Capital IQ 2022
All news about MIMEDX GROUP, INC.
05/26Leading Independent Proxy Advisory Firm ISS Recommends That MIMEDX Shareholders Vote 'F..
AQ
05/25Leading Independent Proxy Advisory Firm ISS Recommends that MIMEDX Shareholders Vote &l..
AQ
05/24MIMEDX GROUP, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/23MiMedx Group, Inc. - Leading Independent Proxy Advisory Firm Glass Lewis Recommends Tha..
AQ
05/20MiMedx Says Glass Lewis Recommends in Favor of Director Nominees, Say-on-Pay Proposal
MT
05/20Leading Independent Proxy Advisory Firm Glass Lewis Recommends that MIMEDX Shareholders..
AQ
05/20Glass Lewis & Co Supports MiMedx Group Inc Nominees and Proposals
CI
05/18MIMEDX Investor Presentation Highlights Clear Strategy for Value Creation
AQ
05/18MiMedx Group Files an Investor Presentation to Shareholders
CI
05/18Prescience Point Capital Management Calls on MiMedx to Confirm the Company Has Received..
PR
More news
Analyst Recommendations on MIMEDX GROUP, INC.
More recommendations
Financials (USD)
Sales 2022 273 M - -
Net income 2022 -30,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -13,7x
Yield 2022 -
Capitalization 431 M 431 M -
Capi. / Sales 2022 1,58x
Capi. / Sales 2023 1,38x
Nbr of Employees 811
Free-Float 97,9%
Chart MIMEDX GROUP, INC.
Duration : Period :
MiMedx Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIMEDX GROUP, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 3,83 $
Average target price 14,17 $
Spread / Average Target 270%
EPS Revisions
Managers and Directors
Timothy R. Wright Chief Executive Officer & Director
Peter M. Carlson Chief Financial Officer
M. Kathleen Behrens Wilsey Chairman
David H. Mason Chief Medical Officer
Scott M. Turner Vice President-Procurement
Sector and Competitors
1st jan.Capi. (M$)
MIMEDX GROUP, INC.-36.59%405
GILEAD SCIENCES, INC.-10.76%80 866
REGENERON PHARMACEUTICALS, INC.9.70%73 638
VERTEX PHARMACEUTICALS24.65%68 965
MODERNA, INC.-41.86%54 016
LONZA GROUP AG-28.07%42 292